You are here » Home » Companies » Company Overview » Arihant Multi Commercial Ltd

Arihant Multi Commercial Ltd.

BSE: 506113 Sector: Others
NSE: N.A. ISIN Code: INE776N01028
BSE 00:00 | 04 Mar Arihant Multi Commercial Ltd
NSE 05:30 | 01 Jan Arihant Multi Commercial Ltd
OPEN 225.50
PREVIOUS CLOSE 224.30
VOLUME 39200
52-Week high 225.50
52-Week low 0.00
P/E 22430.00
Mkt Cap.(Rs cr) 812
Buy Price 0.00
Buy Qty 0.00
Sell Price 225.10
Sell Qty 2000.00
OPEN 225.50
CLOSE 224.30
VOLUME 39200
52-Week high 225.50
52-Week low 0.00
P/E 22430.00
Mkt Cap.(Rs cr) 812
Buy Price 0.00
Buy Qty 0.00
Sell Price 225.10
Sell Qty 2000.00

Arihant Multi Commercial Ltd. (ARIHANTMULTI) - Chairman Speech

Company chairman speech

CHAIRMAN AND MANAGING DIRECTOR

As required by Clause 49 of Listing Agreement the Managing Director and CEO’sDeclaration for Code of Conduct is given below:

To

The Members of

Lifeline Drugs and Pharma Limited

(a) We have reviewed financial statements and the cash flow statement for the year andthat to the best of our knowledge and belief:

(i) these statements do not contain any materially untrue statement or omit anymaterial fact or contain statements that might be misleading;

(ii) these statements together present a true and fair view of the company’saffairs and are in compliance with existing accounting standards applicable laws andregulations.

(b) There are to the best of our knowledge and belief no transactions entered into bythe company during the year which are fraudulent illegal or violative of thecompany’s code of conduct.

(c) We accept responsibility for establishing and maintaining internal controls forfinancial reporting and that we have evaluated the effectiveness of internal controlsystems of the company pertaining to financial reporting and we have disclosed to theauditors and the Audit Committee deficiencies in the design or operation of such internalcontrols if any of which we are aware and the steps we have taken or propose to take torectify these deficiencies.

(d) We have indicated to the auditors and the Audit committee

(i) significant changes in internal control over financial reporting during the year;

(ii) significant changes in accounting policies during the year and that the same havebeen disclosed in the notes to the financial statements; and

(iii) instances of significant fraud of which we have become aware and the involvementtherein if any of the management or an employee having a significant role in thecompany’s internal control system over financial reporting.

By order of the Board
For LIFELINE DRUGS AND PHARMA LIMITED
Alok Kr. Behera
(DIN: 00272675)
May 27 2014 Managing Director